Results 91 to 100 of about 29,030 (239)

Back Again to the Future: A New Era for Cerebroprotection

Annals of Neurology, EarlyView.
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley   +1 more source

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation

Case Reports in Neurological Medicine, 2014
Background. Natalizumab treatment is frequently discontinued and replaced by alternative medication in multiple sclerosis (MS) patients having a high risk of progressive multifocal leukoencephalopathy (PML). Case Presentation.
J. Killestein, A. Vennegoor, A. E. L. van Golde, R. L. J. H. Bourez, M. L. B. Wijlens, M. P. Wattjes   +5 more
doaj   +1 more source

Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?

Multiple Sclerosis and Related Disorders, 2020
The disease caused by the new coronavirus SARS-CoV-2 (COVID-19) is currently spread worldwide . Recent data supports SARS-CoV-2 may use integrins to enter human cells.
C. Aguirre, V. Meca-Lallana, Ana Barrios-Blandino, B. del Rio, J. Vivancos   +4 more
semanticscholar   +1 more source

Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective To assess real‐world effectiveness of switching disease‐modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Methods Of 2615 pediatric‐onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric
Aaron W. Abrams, Michael Waltz, T. Charles Casper, Gregory Aaen, Leslie A. Benson, Eva‐Chava M. Bernfeld, Leigh E. Charvet, Tanuja Chitnis, Carla Francisco, Mark P. Gorman, Jennifer S. Graves, Lauren Krupp, Kimberly O'Neill, Timothy E. Lotze, Soe Mar, Jayne Ness, Mary Rensel, Moses Rodriguez, John Rose, Alice Rutatangwa, Teri Schreiner, Nikita Shukla, Jan‐Mendelt Tillema, Bianca Weinstock‐Guttman, Yolanda Wheeler, Emmanuelle Waubant, Kristen M. Krysko, on behalf of the US Network of Pediatric MS Centers   +27 more
wiley   +1 more source

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod

Therapeutic Advances in Neurological Disorders, 2018
Background: Natalizumab significantly reduces the disease activity in patients with relapsing-remitting multiple sclerosis but due to the risk of progressive multifocal leukoencephalopathy it is often discontinued.
Lara Diem, Krassen Nedeltchev, Timo Kahles, Lutz Achtnichts, Oliver Findling   +4 more
doaj   +1 more source

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years

Neurological Sciences, 2021
Comparative effectiveness of natalizumab and fingolimod over a follow-up longer than 2 years has been not addressed yet. To compare the effect on no evidence of disease activity (NEDA-3) in relapsing-remitting multiple sclerosis (RRMS) patients treated ...
T. Guerra, F. Caputo, B. Orlando, D. Paolicelli, M. Trojano, P. Iaffaldano   +5 more
semanticscholar   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy [PDF]

, 2014
Natalizumab-induced progressive multifocal leukoencephalopathy (PML) appears to be unleashed by complex interactions between viral and immunological host factors leading the latent form of JC virus to become pathogenic.
A.SOTTINI, D.BERTOLI, F.SERANA, L.CAIMI, L.IMBERTI, M. VAGLIO TESSITORE, M.CHIARINI, R.CAPRA, V.GIUSTINI   +8 more
core   +1 more source

Improving risk‐stratification of natalizumab‐associated PML

Annals of Clinical and Translational Neurology, 2021
Based on publicly available data, we reevaluated current algorithms for stratifying the risk of progressive multifocal leukoencephalopathy (PML) in natalizumab‐treated patients with multiple sclerosis, and found that there are a number of issues.
Bastian Tugemann, J. Berger
semanticscholar   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source